DIRS.INFO The most relevant business & tech news

☆ These global stocks are forming the bullish 'golden cross' signal — and have risen every time in the past
▼ + stars: | 2023-11-30 | by ( Ganesh Rao | ) www.cnbc.com time to read: +4 min

The phenomenon, known as a "golden cross," occurs when a stock's 50-day moving average share price rises above the longer-term 200-day moving average. It comes at a time when the S & P 500 has rallied by nearly 10% from a recent low, and charting analysts expect to see the index rise further . The stocks below are about to signal the golden cross pattern. Canadian stock Descartes Systems rose 7% on average in the month after the golden cross. The stock's price action has shown the golden cross forming seven times over the past decade.

Persons: Kevin Krishnaratne, David Weiss, Shagun Singh, Michael Werner, Hayley Tam Organizations: CNBC, Descartes Systems, Stryker Corporation, Deutsche, Nasdaq, Scotiabank, Stryker, RBC, UBS, CNBC Pro Locations: Canadian, Finland, Denmark, Norway, Sweden, Singapore

☆ Buy this electrotherapy stock for more than 62% upside, RBC Capital Markets says
▼ + stars: | 2023-10-16 | by ( Brian Evans | ) www.cnbc.com time to read: +1 min

RBC Capital Markets thinks Zynex stock could grow if the company taps into the patient monitoring market. The firm initiated coverage of the electrotherapy stock with an outperform rating and a $13 per share price target in a Sunday note. Zynex stock has slipped nearly 43% from the start of the year. ZYXI YTD mountain Zynex stock. Analyst Shagun Singh says while the company is already a player in the electrotherapy market in the U.S., Zynex could potentially capitalize on the patient monitoring market worth nearly $4 billion.

Persons: Zynex, Shagun Singh, ZYXI, Singh, CNBC's Michael Bloom Organizations: RBC Capital Markets Locations: U.S

☆ This health care giant has 'unlocked potential' after a recent spinoff, RBC says
▼ + stars: | 2023-10-05 | by ( Pia Singh | ) www.cnbc.com time to read: +2 min

Johnson & Johnson is a buy after the company's consumer business spinoff earlier this year, according to RBC Capital Markets. The firm initiated Johnson & Johnson with an outperform rating and $178 price target, which suggests shares can climb about 14.5% from Wednesday's close. This separation has "unlocked potential" for Johnson & Johnson going forward, analyst Shagun Singh said. Singh also said the company's pharma franchise is poised to deliver competitive growth and that its medtech division is on pace to achieve "top-tier growth and profitability." The analyst added that Johnson & Johnson is trading below its historical multiples despite its improved financial profile since its Kenvue spinoff and that the company has potential upside from further M & A activity.

Persons: Johnson, Shagun Singh, Singh, —, — CNBC's Michael Bloom Organizations: RBC Capital Markets, Johnson, Pharma, company's pharma Locations: Wednesday's

☆ Stocks making the biggest moves midday: Rivian, Orchard Therapeutics, Lamb Weston and more
▼ + stars: | 2023-10-05 | by ( Lisa Kailai Han | ) www.cnbc.com time to read: +4 min

Rivian said it anticipates revenue to range between $1.29 billion and $1.33 billion, versus the $1.3 billion forecast by analysts polled by LSEG, formerly known as Refinitiv. Clorox — Shares dropped 7.7% on Thursday, one day after the product maker offered worse fiscal first-quarter guidance than analysts polled by FactSet expected. Oculis — Shares rose 3.4% after Stifel initiated coverage of the biopharma company with a buy rating and $35 target price. Johnson & Johnson — Shares of the health-care giant added 0.8% in midday trading after RBC initiated company coverage with an outperform rating. Instacart — Instacart fell 2.9% after Bernstein initiated coverage of the company at a market perform rating, noting that increased competition challenged the delivery company's strong digital advertising business.

Persons: Rivian, Clorox, FactSet, Kyowa Kirin, Vestis, Oculis, Wedbush, Shagun Singh, Lamb Weston — Lamb Weston, Tom Werner, Instacart — Instacart, Bernstein, — CNBC's Brian Evans, Alex Harring, Tanaya Macheel, Sarah Min, Jesse Pound, Pia Singh, Samantha Subin, Michelle Fox Theobald Organizations: Rivian, Rivian Automotive, LSEG, Exxon Mobil —, UWM Holdings, BTIG, Orchard Therapeutics, Kyowa, Redburn, JPMorgan, Carrier, Bank of America, Johnson, RBC, Constellation Locations: Aramark, Europe

Abbott CEO Robert Ford said the great momentum in device and diagnostics sales during the quarter was due to improving market conditions in healthcare. Rival J&J's (JNJ.N) medical device segment also topped estimates, aided by a recovery in demand for medical procedures. Shares of rival medical device makers Medtronic (MDT.N) and Boston Scientific Corp (BSX.N) rose nearly 3%. Abbott clocked quarterly sales for its medical devices at $4.3 billion, with $1.3 billion coming from diabetes device Freestyle Libre, beating analysts' estimates of $4.10 billion. Abbott's adjusted profit of $1.08 per share in the quarter beat analysts' estimates of $1.05.

Persons: Robert Ford, J, Shagun Singh, Abbott, Khushi Mandowara, Pooja Desai Organizations: Abbott Laboratories, RBC Capital Markets, Boston Scientific Corp, U.S, Thomson Locations: Michigan, Bengaluru

☆ Intuitive Surgical beats first-quarter sales on higher procedure volumes
▼ + stars: | 2023-04-18 | by ( Sriparna Roy | ) www.reuters.com time to read: +2 min

April 18 (Reuters) - Intuitive Surgical Inc (ISRG.O) beat estimates for first-quarter sales on Tuesday as the surgical robot maker recorded a rise in total procedure volumes. The company reported quarterly sales of $1.70 billion, beating analysts' estimates of $1.60 billion, according to IBES Refinitiv data. The medical device maker posted a 26% growth in procedure volumes of its surgical robot da Vinci in the first quarter through March from a year earlier. Investors are eyeing the launch of company's new multiport surgical robot, which could be a potential near-term catalyst, analysts said after Intuitive in January told its next generation system is not expected to be launched this year. Excluding items, Intuitive earned $1.23 per share in the first quarter, above analysts' average estimate of $1.20 per share, according to IBES data from Refinitiv.

RBC Capital Markets anticipates that the next quarter could be choppy for stocks, but the firm shared its list of high-conviction names to navigate the volatility. With these concerns in mind, RBC shared a list of high-conviction stocks that it says are well-positioned to offer upside this quarter. Below are 10 of the names: Alnylam Pharmaceuticals and biotech engineering stock Boston Scientific are new additions to RBC's list of high-conviction names. RBC analyst Shagun Singh said Boston Scientific is "positioned to drive consistent double-digit EPS growth," with upcoming device launches and trial data readouts to act as catalysts. On the energy front, RBC named oil company Diamondback Energy as one of its top picks for the quarter.

Search resuls for: "Shagun Singh"

7 mentions found